Skip to main content
SpringerLink
Log in

Safety and efficacy of Rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece

  • Short Communication
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Lupus nephritis (LN) is the major determinant of outcome in pediatric systemic lupus erythematosus (pSLE), and its treatment remains a challenge. The aim of this study was to report the experience of our center in treating with rituximab (RTX) SLE patients with severe LN. Four pSLE patients with biopsy-proven LN, who are refractory to conventional immunosuppressive treatment, received four doses of 375–500 mg/m2 RTX, 2–3 weeks apart. All patients were concurrently receiving corticosteroids (CSs) and mycophenolate mofetil. Patients’ clinical and laboratory findings were recorded at RTX initiation, after each infusion and at 3.4 ± 2.1 month intervals thereafter. pSLE activity was assessed using the European Consensus Lupus Activity Measurement (ECLAM), while LN activity using 24-hour urine protein excretion and serum cystatin C. Patients were followed up for 6–21 months (median: 16 months). Full Β-cell depletion was noticed 2–4 weeks after RTX initiation and lasted 4–7 months. All patients achieved complete LN remission 3.5 months (range: 2–4) after RTX initiation, which was retained in 3 patients through the follow-up period. One patient relapsed 15 months after RTX initiation and received one additional RTX dose. ECLAM scores and CSs doses were markedly reduced in all patients, while complement levels were increased. No side effects or infections were observed. In conclusion, RTX is an alternative, safe and efficient treatment for refractory LN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Papadimitraki ED, Isenberg DA (2009) Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol 5:391–403

    Article  PubMed  Google Scholar 

  2. Sousa E, Isenberg D (2009) Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. Best Pract Res Clin Rheumatol 23:563–574

    Article  PubMed  Google Scholar 

  3. Marks SD, Tullus K (2010) Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr 99:967–974

    Article  PubMed  CAS  Google Scholar 

  4. García-Carrasco M, Jiménez-Hernández M, Escárcega RO et al (2009) Use of Rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 8:343–348

    Article  PubMed  Google Scholar 

  5. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18:767–776

    Article  PubMed  CAS  Google Scholar 

  6. Gillis JZ, Dall’era M, Gross A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with Rituximab: a case series. Arthr Rheum 57:538–542

    Article  CAS  Google Scholar 

  7. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 40:1725

    Article  CAS  Google Scholar 

  8. Brunner HI, Silverman ED, Bombardier C, Feldman BM (2003) European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthr Rheum 49:335–341

    Article  Google Scholar 

  9. Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250

    Article  PubMed  Google Scholar 

  10. Roos JF, Doust J, Tett SE, Kirkpatrick CM (2007) Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children–a meta-analysis. Clin Biochem 40:383–391

    Article  PubMed  CAS  Google Scholar 

  11. Pepper R, Griffith M, Kirwan C et al (2009) Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24:3717–3723

    Article  PubMed  CAS  Google Scholar 

  12. Willems M, Haddad E, Niaudet P et al (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623–627

    Article  PubMed  CAS  Google Scholar 

  13. Saito K, Nawata M, Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y (2003) Successful treatment with anti-CD20 monoclonal antibody (Rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 12:798–800

    Article  PubMed  CAS  Google Scholar 

  14. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O et al (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthr Res Ther 8:R83

    Article  Google Scholar 

  15. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M et al (2010) Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 19:213–219

    Article  PubMed  CAS  Google Scholar 

  16. Lu TY, Ng KP, Cambridge G et al (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthr Rheum 61:482–487

    Article  Google Scholar 

  17. Terrier B, Amoura Z, Ravaud P et al (2010) Safety and efficacy of Rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. Arthr Rheum 62:2458–2466

    Article  CAS  Google Scholar 

  18. Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K (2008) B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 93:401–406

    Article  PubMed  CAS  Google Scholar 

  19. Marks SD, Patey S, Brogan PA et al (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthr Rheum 52:3168–3174

    Article  CAS  Google Scholar 

  20. Marks SD, Tullus K (2006) Successful outcomes with Rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol 21:598–599

    Article  PubMed  Google Scholar 

  21. Iwata S, Saito K, Tokunaga M et al (2011) Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B Cell Depletion therapy with Rituximab. J Rheumatol 38:633–641

    Article  PubMed  CAS  Google Scholar 

  22. Anolik JH, Barnard J, Owen T et al (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthr Rheum 56:3044–3056

    Article  CAS  Google Scholar 

  23. Liossis SN, Sfikakis PP (2008) Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127:280–285

    Article  PubMed  CAS  Google Scholar 

  24. Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP (2009) Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 24:2157–2160

    Article  PubMed  CAS  Google Scholar 

  25. Ramos-Casals M, Díaz-Lagares C, Khamashta MA (2009) Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum 61:1281–1282

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. First Department of Pediatrics, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Str, 54642, Thessaloniki, Greece

    Maria Trachana, Artemis Koutsonikoli, Evagelia Farmaki, Nikoleta Printza, Vasiliki Tzimouli & Fotios Papachristou

Authors
  1. Maria Trachana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Artemis Koutsonikoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evagelia Farmaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikoleta Printza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vasiliki Tzimouli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fotios Papachristou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Trachana.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trachana, M., Koutsonikoli, A., Farmaki, E. et al. Safety and efficacy of Rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 33, 809–813 (2013). https://doi.org/10.1007/s00296-011-2239-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-2239-6

Keywords

Search

Navigation